ARTICLE | Clinical News

Collategene beperminogene perplasmid: Phase III started

October 27, 2014 7:00 AM UTC

AnGes began a double-blind, placebo-controlled, international Phase III trial to evaluate Collategene injected into the affected limb for 36 months in about 500 patients with CLI. AnGes has an SPA from FDA for the trial. Collategene has Fast Track designation in the U.S. for CLI. ...